AimMax Therapeutics, Inc. Email Format
Pharmaceutical ManufacturingNorth Carolina, United States2-10 Employees
AimMax Therapeutics, Inc. operates in the pharmaceutical sector with a focus on researching and developing drug candidates at multiple stages of development. It pursues in-licensing or co-development partnerships with strategic collaborators to advance its programs. Based in Durham, North Carolina, the company is run by a small team and emphasizes external collaboration to bring its projects forward. In November 2022, AimMax Therapeutics, in collaboration with Formosa Pharmaceuticals, announced the completion of a pre-NDA meeting with the US FDA for its lead program, APP13007. APP13007 is a 14-day, twice-daily eyedrop intended to treat inflammation and pain after ocular surgery.